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Self-harm is a potentially lethal symptom of borderline personality disorder (BPD) that
often improves with dialectical behavior therapy (DBT). While DBT is effective for
reducing self-harm in many patients with BPD, a small but significant number of patients
either does not improve in treatment or ends treatment prematurely. Accordingly, it is
crucial to identify factors that may prospectively predict which patients are most likely
to benefit from and remain in treatment. In the present preliminary study, 29 actively
self-harming patients with BPD completed brain-imaging procedures probing activation
of the prefrontal cortex (PFC) during impulse control prior to beginning DBT and after
7 months of treatment. Patients that reduced their frequency of self-harm the most
over treatment displayed lower levels of neural activation in the bilateral dorsolateral
prefrontal cortex (DLPFC) prior to beginning treatment, and they showed the greatest
increases in activity within this region after 7 months of treatment. Prior to starting DBT,
treatment non-completers demonstrated greater activation than treatment-completers
in the medial PFC and right inferior frontal gyrus. Reductions in self-harm over the
treatment period were associated with increases in activity in right DLPFC even after
accounting for improvements in depression, mania, and BPD symptom severity. These
findings suggest that pre-treatment patterns of activation in the PFC underlying impulse
control may be prospectively associated with improvements in self-harm and treatment
attrition for patients with BPD treated with DBT.
Keywords: borderline personality disorder, self-harm, dialectical behavior therapy, prefrontal cortex, impulse
control, fNIRS
INTRODUCTION
Borderline personality disorder (BPD) is a mental disorder characterized by difficulties with
emotion regulation, impulse control, self-image and interpersonal relationships (American
Psychiatric Association, 2013). Deliberate self-injury with or without the intent to die, commonly
referred to as self-harm, occurs in 63–80% of patients with BPD (Chapman et al., 2005).
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A treatment that reduces self-harm in patients with BPD is
dialectical behavior therapy (DBT), an empirically-supported
psychotherapy intended to improve behavioral control and
emotion regulation (Linehan et al., 2006; McMain et al.,
2009). Whereas DBT is an effective treatment, outcomes in
clinical trials represent averages and the effect on any one
individual may be larger or smaller than the average effect.
Response heterogeneity may be explained in part by meta-
analytic evidence that suggests patients who begin but do not
complete treatment have worse outcomes over time (McMurran
et al., 2010). Additionally, more than one-quarter of patients with
BPD in DBT end treatment prematurely (Linehan et al., 2006;
McMain et al., 2009). Therefore, determining factors that predict
treatment response and attrition will be useful for advancing our
understanding of how to adapt treatment to address the needs of
individuals.
Neuroimaging holds promise for isolating markers of
brain function that predict treatment outcomes for self-
harming patients with BPD. In major depression, psychotherapy
studies examining neural activation while viewing negative
emotional pictures have found that activity in amygdala, anterior
cingulate, and dorsolateral prefrontal cortex (DLPFC), may be
prospectively associated with responses to cognitive-behavioral
treatments (for a review, see DeRubeis et al., 2008). Patients
with BPD show neural systems dysfunctions in similar regions
while processing negative emotions (Ruocco et al., 2013) and
two small preliminary studies suggest that activity in these same
regions may be modulated by DBT and potentially associated
with BPD symptom improvements (Schnell and Herpertz, 2007;
Goodman et al., 2014). To our knowledge, no studies have
yet examined neural activation during response inhibition as a
potential predictor of psychotherapy outcomes for any mental
disorder. Deficits in response inhibition may underlie BPD
and self-harm (Ruocco, 2005; Ruocco et al., 2012; Williams
et al., 2015) and considering that DBT is intended to improve
behavioral control and reduce self-harm in BPD, activation
in neural regions underlying response inhibition, specifically
motor inhibitory control, may conceivably show associations
with treatment outcomes.
The current preliminary study probed activation in the
PFC associated with motor inhibitory control before patients
enrolled in a standard outpatient DBT program and again
after 7 months of treatment. The primary aims of the study
were to determine whether pre-treatment activation in the
PFC was associated with: (1) reductions in self-harm through
treatment; and (2) attrition from treatment. We hypothesized
that patients with BPD who go on to demonstrate the greatest
reductions in self-harm would show lower pre-treatment activity
in lateral regions of the PFC underlying impulse control,
consistent with the notion that these patients may have the
most to gain from a treatment intended to improve behavioral
control. Furthermore, we anticipated that patients who initiate
treatment but do not complete treatment would display higher
levels of activity in these same regions of the PFC, which
could represent a neurophysiological marker signifying increased
risk for treatment attrition in DBT. Exploratory analyses
investigated associations between shifts in PFC activation and
changes in self-harm between pre-treatment and seven-month
assessments.
MATERIALS AND METHODS
Participant Characteristics
The current study adopted a naturalistic design by recruiting
patients with BPD that were being treated as part of regular
clinical services in the BPD Clinic at the Centre for Addiction
and Mental Health in Toronto, Canada. Thirty-one participants
with BPD reporting at least seven episodes of self-harm in the
past 12 months consented and enrolled in the study. Figure 1
depicts flow of participants through the study. Individuals
not eligible for the study based on a phone screen did not
significantly differ from eligible individuals according to age
[t(52) = 0.89, p = 0.38] or gender (p = 0.69, two-tailed Fisher’s
exact test). Participants eligible for the study were 18–65 years
old, fluent in English, capable to provide written informed
consent, had a current (at least past 5 years) diagnosis of
BPD, and reported at least seven episodes of self-harm in the
past year. Participants were excluded if they had a lifetime
psychotic disorder, current substance dependence, neurological
or medical illness that could impact brain function (e.g.,
significant head trauma, seizure disorder, or stroke), significant
manual, visual or hearing impairment, or estimated IQ less
than 80 on the Wechsler Test of Adult Reading (Wechsler,
2002).
Procedure
The present study was approved by the Research Ethics Board
of the Centre for Addiction and Mental Health, and the
Social Sciences, Humanities and Education Research Ethics
Board at the University of Toronto. After complete description
of the study to the participants, written informed consent
was obtained. Participants completed the Structured Clinical
Interview for DSM-IV Axis I Disorders—Patient Edition (First
et al., 2002), Structured Interview for DSM-IV Personality
(Pfohl et al., 1995), Montgomery–Åsberg Depression Rating
Scale (MADRS; Montgomery and Asberg, 1979), Young Mania
Rating Scale (YMRS; Young et al., 1978), and Zanarini BPD
Rating Scale (ZAN-BPD; Zanarini et al., 2003). Frequencies
of self-harming behaviors were assessed with a modified
Parasuicide Count (Comtois and Linehan, 1999). Diagnostic
assessments were administered by Master’s and doctoral level
research assistants directly supervised by a licensed psychologist
(ACR). Results of diagnostic assessments were reviewed in a
multidisciplinary ‘‘best estimate’’ diagnostic meeting (Klein et al.,
1994).
Participants completed functional near-infrared spectroscopy
(fNIRS) neuroimaging procedures prior to beginning DBT and
after approximately 7 months of treatment (M = 30.20 weeks,
SD = 13.25). A 7-month timeframe was chosen because the
most substantial reductions in self-harm are observed well
within this period for self-harming patients treated with DBT
(McMain et al., 2009). fNIRS is a neuroimaging technique that
introduces light in the near-infrared range at the level of the
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FIGURE 1 | Participant flow chart detailing completion of treatment and study procedures. Note: An asterisk (∗) indicates that the participant did not attend
laboratory procedures but did complete 7 months of dialectical behavior therapy (DBT).
scalp and monitors changes in the optical properties of the
local vasculature according to the differential absorption and
back-scattering of photons. The fNIR Imager 1000r (fNIR
Devices, Potomac,MD, USA) is a continuous-wave fNIRS system
that was used to deliver two wavelengths of light (730 and
850 nm) that were measured continuously at 500 ms intervals
(2 Hz) in 16 channels (4 light sources and 10 photo-detectors).
Source-detector separation was 2.5 cm, yielding a 1.25 cm depth
of penetration. The probe (18 cm × 6 cm × 0.8 cm) was
aligned with electrode positions F7, FP1, FP2, and F8 (which
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TABLE 1 | Rates of self-harm for patients with borderline personality
disorder (N = 18) prior to beginning treatment and after 6 months of
dialectical behavior therapy.
% Endorsed Monthly % of All % Suicidal
Rate Self-Harm
M (SD)
Before starting treatment
Cutting 66.67 2.56 (7.06) 37.74 0
Overdose 27.78 0.04 (0.07) 0.54 12.5
Hanging 1.11 0.02 (0.06) 0.27 25
Asphyxiation 5.56 0.00 (0.02) 0.07 100
Burning 27.78 0.14 (0.36) 1.09 100
Jumping 5.56 0.00 (0.02) 0.07 0
Shooting 5.56 0.00 (0.02) 0.07 0
Drowning 5.56 0.01 (0.04) 0.14 100
Stabbing 16.67 0.06 (0.20) 0.82 0
Hitting 66.67 1.50 (3.46) 22.07 0
Other 55.56 2.52 (4.26) 37.13 0
After 7 months of treatment
Cutting 38.89 4.66 (16.92) 74.22 0
Overdose 16.67 0.06 (0.04) 0.94 0
Hanging 0 0.00 (0.00) 0 0
Asphyxiation 0 0.00 (0.00) 0 0
Burning 11.11 0.03 (0.09) 0.31 50
Jumping 0 0.00 (0.00) 0 0
Shooting 0 0.00 (0.00) 0 0
Drowning 0 0.00 (0.00) 0 0
Stabbing 11.11 0.23 (0.89) 3.59 0
Hitting 38.89 0.56 (1.23) 8.91 35.09
Other 55.56 0.75 (1.10) 12.03 1.3
Note: % Endorsed = proportion of patients that endorsed each type of self-harm. %
of All Self-Harm = proportion of a specific type of self-harm relative to the frequency
of all self-harm. % Suicidal = proportion of self-harm with suicidal intent. Patients
showed significant reductions in hitting (z = −2.50, p = 0.01; related- samples
Wilcoxon Signed Rank Test) and other self-harm (z = −2.20, p = 0.03; related-
samples Wilcoxon Signed Rank Test) after treatment.
correspond to Brodmann areas 9, 10, 45, and 46, respectively)
based on the international 10–20 electroencephalography system
(Jasper, 1958). Specific details regarding placement of the
probe are provided in Ayaz et al. (2006). Participants sat in
a dark room in front of a computer monitor. After securing
the fNIRS sensor pad on the participant’s forehead using
Velcror straps, participants were asked to directly stare at
a crosshair fixation for 10 s to establish baseline parameters.
Participants then completed the Scarborough Non-Affective
Go/No-go Task, a previously validated measure of motor
inhibitory control known to activate bilateral medial and
inferior frontal gyri during response inhibition (Rodrigo et al.,
2014). The task was chosen for its relevance to controlling
motor behaviors in participants with BPD who are actively
engaging in physically self-injurious behaviors. Briefly, the task
presents participants with either green (‘‘go’’) or red (‘‘no-
go’’) circles at the center of a computer monitor and asks
them to press a button with their right hand to ‘‘go’’ stimuli
(90 trials) and withhold their response to ‘‘no-go’’ stimuli
(30 trials). The inter-trial interval was jittered at increments
of 500 ms (ranging from 4000–6000 ms, M = 5000 ms)
to discourage anticipatory responding. From the raw light
intensity measurements, relative concentrations of oxygenated
hemoglobin (oxy-Hb) were calculated using the modified
TABLE 2 | A summary of psychiatric diagnostic comorbidities within the
final sample (N = 29).
Disorder n Percent in final sample
Bipolar I disorder 2 6.90%
Bipolar II disorder 1 3.45%
Major depressive disorder
Current 13 44.83%
Past 10 34.48%
Dysthymic disorder 1 3.45%
Alcohol abuse
Current 1 3.45%
Past 4 13.79%
Alcohol dependence (past) 13 44.83%
Substance dependence (past) 7 24.14%
Sedative 1 3.45%
Cannabis 6 20.69%
Opioid 1 3.45%
Cocaine 1 3.45%
Stimulant 1 3.45%
Polysubstance dependence (past) 1 3.45%
Panic disorder
Current 9 31.03%
Past 2 6.90%
Agoraphobia without panic disorder (current) 2 6.90%
Social phobia
Current 1 3.45%
Past 2 6.90%
Specific phobia
Current 1 3.45%
Past 2 6.90%
Obsessive-compulsive disorder
Current 6 20.69%
Past 3 10.34%
Posttraumatic stress disorder
Current 12 41.38%
Past 3 10.34%
Generalized anxiety disorder 3 10.34%
Anorexia nervosa (past) 4 13.79%
Bulimia nervosa
Current 1 3.45%
Past 4 13.79%
Paranoid personality disorder 3 10.34%
Antisocial personality disorder 5 17.24%
Avoidant personality disorder 8 27.59%
Dependent personality disorder 4 13.79%
Obsessive-compulsive personality disorder 3 10.34%
Beer-Lambert law (Cope and Delpy, 1988), which calculates
the absorption of light for a given substance’s concentration.
Image reconstruction was rendered using topographic tools
available in fNIRSoftr Professional Edition (Ayaz, 2010), which
maps fNIRS activation data onto magnetic resonance imaging
templates.
Participants enrolled in a standard outpatient DBT
program that included both individual (1 h/week) and group
psychotherapy (2 h/week; details of the treatment program
are described in McMain et al., 2009). Overall, this treatment
focused on eliminating behavioral dysregulation through the
development of more effective coping strategies, which in
turn are balanced with validation. Twenty-one participants
completed treatment; however, pre-treatment neuroimaging
data were unavailable for one participant that provided a
positive urine toxicology screen and was ineligible to complete
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TABLE 3 | Multilevel analyses comparing pre-treatment levels of
oxygenated hemoglobin in all 16 channels during No-Go and cross-hair
fixation blocks.
fNIRS b SE df t R2
β
Channel
1 −0.0961 0.0133 35142.22 −7.2510∗∗ 0.0015
2 −0.0511 0.0136 37903.01 −3.7550∗∗ 0.0004
3 −0.0489 0.0127 38347.04 −3.8460∗∗ 0.0004
4 −0.0743 0.0144 37447.01 −5.1680∗∗ 0.0007
5 0.0107 0.0126 38394.07 0.8520 0.0000
6 −0.0399 0.0146 37936.03 −2.7250∗ 0.0002
7 0.0224 0.0129 36265.72 1.7360 0.0001
8 −0.0152 0.0160 32284.60 −0.9520 0.0000
9 0.0376 0.0147 34075.36 2.5560∗ 0.0002
10 0.0095 0.0148 36608.12 0.6420 0.0000
11 0.0081 0.0118 38263.18 0.6840 0.0000
12 −0.0300 0.0135 37868.06 −2.2200 0.0001
13 −0.0168 0.0121 39050.07 −1.3960 0.0000
14 −0.0838 0.0157 39148.03 −5.3480∗∗ 0.0007
15 −0.0227 0.0142 36182.99 −1.6010 0.0001
16 0.0010 0.0157 38275.14 0.0640 0.0000
Note: ∗∗p < 0.001, ∗p < 0.05. All models were estimated with an unstructured
covariance matrix and the Satterthwaite method of estimating degrees of freedom.
Significance levels were corrected using the False Discovery Rate approach.
subsequent study procedures. Seven-month neuroimaging data
were available for 18 participants who completed treatment
(‘‘treatment completers’’). Neuroimaging data were unavailable
at the 7-month assessment for two additional participants who
continued to be enrolled in treatment because one provided a
positive urine drug screen at the 7-month assessment and the
second was lost to follow-up but clinic notes indicated that the
participant remained in treatment. Five participants dropped
out of treatment and four qualified for the study but never
initiated treatment after completing pre-treatment diagnostic
and neuroimaging assessments (collectively referred to as
‘‘treatment non-completers’’, n = 9). Participants who completed
treatment did not differ from non-completers in pre-treatment
rate of self-harm (z = 1.06, p = 0.29; independent-samples
Mann-Whitney U Test) or in age [t(28) = 1.98, p = 0.06], gender
(p = 0.25, two-tailed Fisher’s exact test), or IQ [t(28) = 0.72,
p = 0.47].
Statistical Analysis
Neuroimaging data were analyzed using multilevel generalized
linear models that nested all observations (µmol/l oxy-Hb
measured at 2 Hz) within participants. The first set of analyses
investigated pre-treatment motor inhibitory control -related PFC
activation for all participants who completed neuroimaging. The
neural activation changes that were observed for those who
completed 7 months of treatment were then investigated by
examining interactions between Condition (no-go vs. crosshair
fixation) and Time (pre-treatment vs. 7-month assessments)
in each of 16 channels. Simple effects of the significant
interactions from this set of analyses were then probed (Aiken
et al., 1991) to examine activation patterns prior to treatment,
and separately, after 7 months of treatment. The second
set of analyses examined the three-way interaction between
Condition, Time and Change-in-Self-Harm-Rate. Treatment
completers were compared with non-completers by exploring
significant interactions between treatment completion status
and inhibitory control-related neural activation in the PFC.
Significant interactions were subsequently investigated to
identify patterns of activation displayed by participants who
showed higher symptom improvement (i.e., 1 SD above the
mean) and lower symptom improvement (i.e., 1 SD below
the mean) separately at each assessment time point. The
final set of analyses examined differences in PFC activation
between participants who completed 7 months of treatment
vs. those who did not (Condition and Treatment-Completion-
Status interaction), and then probing simple effects based on
significant interactions. Type I error for whole-probe interaction
analyses was controlled using the False-Discovery Rate approach
(Benjamini and Hochberg, 1995; Benjamini et al., 2001) and p-
values less than 0.05 were reported as statistically significant.
Effect sizes (semi-partial R2) are reported where appropriate.
RESULTS
Participant Characteristics
The mean age of participants was 28.65 (SD = 10.04) and
their estimated IQ was 105.68 (SD = 8.20). Most participants
were women (90.30%) and right-hand dominant (87.10%). The
ethnic-racial composition of the sample according to 2011
Canadian census categories was as follows: Black (3.23%), Latin
American (16.13%), South Asian (6.45%), White/Caucasian
(64.52%) and other (9.68%). Table 1 presents frequencies of
subtypes of self-harm and suicidal intent between pre-treatment
and 7-month assessments. Cumulatively, rates of self-harm were
significantly reduced after approximately 7 months of treatment
(z = −3.36, p = 0.001; related-samples Wilcoxon Signed Rank
FIGURE 2 | Areas of reduced activation during response inhibition
(no-go blocks minus cross-hair fixation) in bilateral medial and inferior
frontal gyri and higher activation in medial prefrontal cortex (PFC) for
patients who completed neuroimaging procedures at the
pre-treatment assessment (N = 29).
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FIGURE 3 | PFC activation during response inhibition (no-go blocks minus cross-hair fixation) for patients who completed 7 months of treatment
(N = 18). Left panel (A) displays areas in the PFC showing significant treatment-related changes in activation between pre-treatment and 7-month neuroimaging
assessments (channels with significant Condition × Time interactions). Right panel (B) illustrates PFC activation during response inhibition before starting treatment
(upper) and after 7 months of DBT (lower).
Test). BPD symptom severity did not significantly change from
pre-treatment assessments (ZAN-BPD total score M = 18.25,
SD = 6.51) to 7 months of DBT (M = 13.70, SD = 5.56; t = 1.97,
p = 0.06).
Psychiatric diagnostic co-morbidities for participants
that qualified for the study and completed pre-treatment
psychodiagnostic assessments (n = 29) are presented in Table 2.
A majority of participants (64.71%) who completed treatment
were taking medications (alone or in combination) at the time
of the study: sedatives (n = 4), antidepressants (n = 8), mood
stabilizers (n = 2), and antipsychotics (n = 4).
Participants on average reported moderate depression on
the MADRS (M = 23.43, SD = 8.40) and minimal symptoms
of mania on the YMRS (M = 9.19, SD = 5.78). After
approximately 7 months of DBT, symptoms of depression
(M = 19.43, SD = 7.90) and mania (M = 6.76, SD = 4.61) did
not markedly change (p’s > 0.05, two-tailed repeated-measures
t-tests). Participants reported minimal levels of suicidal ideation
on the Modified Scale for Suicidal Ideation (Miller et al., 1986)
before starting DBT (M = 3.11, SD = 2.61) and after 7 months
of treatment (M = 2.61, SD = 3.35; t = 0.36, p = 0.73).
Treatment completers did not differ from non-completers in
pre-treatment levels of depression, mania, suicidal ideation,
and BPD symptom severity (p’s ≥ 0.23; independent-samples
t-tests).
Behavioral Performances on the Motor
Inhibitory Control Task
Accuracy on the go/no-go task (sum of true positive and true
negative responses) was high for participants with BPD prior to
starting DBT (M = 98.82%, SD = 1.15) and after approximately 7
months of treatment (M = 96.67%, SD = 2.61). More specifically,
the number of commission errors during the no-go condition
was low at pre-treatment (M = 2.44, SD = 2.25), and following
approximately 7 months of treatment (M = 1.00, SD = 1.03).
Participants did not differ in their accuracy (z = −0.12, p = 0.91;
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TABLE 4 | Multilevel analyses in all 16 channels examining the interaction
between Condition (no-go vs. cross-hair fixation) and Time (pre-treatment
vs. 7-month assessments).
fNIRS b SE df t R2
β
Channel
1 0.0671 0.0097 58357.04 6.9430∗∗ 0.0008
2 0.0615 0.0109 61952.94 5.6670∗∗ 0.0005
3 0.0282 0.0094 62573.96 2.9980∗ 0.0001
4 0.0551 0.0112 60260.94 4.9010∗∗ 0.0004
5 −0.0086 0.0098 62525.01 −0.8820 0.0000
6 0.0046 0.0115 62449.96 0.3980 0.0000
7 0.0012 0.0109 59390.52 0.1070 0.0000
8 0.0127 0.0127 54627.41 1.0050 0.0000
9 −0.0038 0.0116 57034.33 −0.3310 0.0000
10 −0.0106 0.0124 58427.21 −0.8600 0.0000
11 0.0204 0.0100 59973.13 2.0500 0.0001
12 0.0400 0.0110 61945.00 3.6290∗∗ 0.0002
13 0.0170 0.0099 61452.01 1.7190 0.0000
14 0.0442 0.0125 63002.99 3.5390∗∗ 0.0002
15 0.0353 0.0106 60197.88 3.3360∗ 0.0002
16 0.0806 0.0128 62765.93 6.2710∗∗ 0.0006
Note: ∗∗p < 0.001, ∗p < 0.05. All models were estimated with an unstructured
covariance matrix and the Satterthwaite method of estimating degrees of freedom.
Significance levels were corrected using the False Discovery Rate approach.
related-samples Wilcoxon Signed Rank Test) or response
times on true positive responses (z = 0.65, p = 0.52; related-
samples Wilcoxon Signed Rank Test) between the pre-treatment
assessment and after 7 months of DBT. Participants, on the
other hand, demonstrated a significant difference between
pre- and post-treatment on commission errors (z = −2.22,
p = 0.03; related-samples Wilcoxon Signed Rank Test). This
finding, however, appeared to be driven by two participants
who demonstrated a noticeable change in commission errors
across the two time points (−23.33% change in commissions;
M = −4.8%, SD = 8.57). Treatment completers did not
differ from non-completers in accuracy (z = −0.10, p = 0.92;
Independent-Samples Mann-Whitney U Test) or response times
on true-positive trials (z =−0.86, p = 0.39; Independent-Samples
Mann-Whitney U Test) on the go/no-go task. Additionally,
no differences were observed between completers and non-
completers with regard to commission errors during the
no-go condition (z = −0.50, p = 0.62; Independent-Samples
Mann-Whitney U Test).
Pre-Treatment PFC Activation and
Changes through Treatment
Before beginning DBT, all participants with BPD who completed
pre-treatment neuroimaging (n = 29) showed less activation
in bilateral DLPFC and more activation in right medial PFC
during response inhibition as compared to cross-hair fixation
(p’s < 0.05; Table 3; Figure 2). For treatment completers
(n = 18), participants also showed less activation in bilateral
DLFPC before beginning treatment, and as shown in Figure 3,
they showed treatment-related increases in activation in more
widespread areas of medial aspects of the DLPFC bilaterally
and right medial PFC. After 7 months of treatment, participants
displayed higher levels of activation during response inhibition
TABLE 5 | Multilevel analyses examining simple effects for channels with
significant interactions between Condition (no-go vs. cross-hair fixation)
and Time (pre-treatment vs. 7-month assessments).
fNIRS b SE df t R2
β
Channel
Pre-Treatment
1 −0.0976 0.0124 58357.18 −7.8800∗∗ 0.0021
2 −0.0525 0.0137 61952.97 −3.8230∗∗ 0.0005
3 −0.0500 0.0119 62573.99 −4.2020∗∗ 0.0006
4 −0.0758 0.0139 60260.97 −5.4620∗∗ 0.0010
12 −0.0306 0.0139 61945.06 −2.1930∗ 0.0002
14 −0.0864 0.0156 63002.98 −5.5350∗∗ 0.0010
15 −0.0215 0.0136 60197.92 −1.5850 0.0001
16 0.0005 0.0162 62766.45 0.0320 0.0000
After 7 months
of treatment
1 0.0366 0.0148 58356.94 2.4660∗ 0.0002
2 0.0705 0.0168 61952.93 4.1940∗∗ 0.0006
3 0.0064 0.0146 62573.94 0.4400 0.0000
4 0.0344 0.0177 60260.92 1.9450 0.0001
12 0.0495 0.0171 61944.96 2.8940∗ 0.0003
14 0.0020 0.0195 63002.99 0.1040 0.0000
15 0.0492 0.0163 60197.85 3.0220∗ 0.0003
16 0.1617 0.0199 62765.59 8.1040∗∗ 0.0021
Note: ∗∗p < 0.001, ∗p < 0.05. All models were estimated with an unstructured
covariance matrix and the Satterthwaite method of estimating degrees of freedom.
Significance levels are FDR corrected.
primarily in right DLPFC and to a lesser extent in the
homologous region in the left PFC (p’s < 0.01). They also
showed higher activation in the right medial PFC (p < 0.01).
The main interactions for these analyses are summarized in
Table 4, while the simple effects analyses are summarized in
Table 5.
Associations between Changes in
Symptom Severity and PFC Activation
Reductions in self-harm were significantly associated
with changes in activation in right DLPFC (Condition ×
Time × Change-in-Self-Harm, p < 0.01). Prior to beginning
DBT, participants who showed the greatest reductions in
self-harm displayed less activation in right DLPFC (p < 0.01)
compared to those with the least improvements in self-harm after
7 months. Whereas participants seeing the greatest reduction
in self-harm had less activation in right DLPFC before starting
treatment, they demonstrated the greatest increase in activation
in this region after 7 months of treatment (p < 0.01). Within a
larger portion of the left DLPFC, a similar pattern of self-harm
associations was found (p’s < 0.01), with the exception that
participants with the greatest and least improvements did not
differ in level of activation before beginning DBT (these findings
are summarized in Figure 4). Statistically controlling for changes
in depression, mania, and BPD symptom severity did not change
the pattern of activation in bilateral PFC and resulted in a more
statistically significant result (Condition × Time × Change-in-
Self-Harm interactions in both regions remained significant,
p’s < 0.01). The main interactions for these analyses are
summarized in Table 6, while the simple effects analyses are
summarized in Table 7.
Frontiers in Human Neuroscience | www.frontiersin.org 7 May 2016 | Volume 10 | Article 220
Ruocco et al. Prefrontal Cortex Activation and Self-Harm
FIGURE 4 | Activation in bilateral medial/inferior frontal gyri that significantly changed with self-harm frequency after 7 months of DBT (significant
Condition × Time × Change-in-Self-Harm interactions). Bar graphs show levels of activity in each cluster of activation for patients who showed high vs. low
improvements in self-harm at pre-treatment and 7-month assessments.
Pre-Treatment Activation Differences
Between Completers and Non-Completers
Compared to participants that either dropped out or did not
initiate treatment (n = 9), participants that completed 7 months
of treatment (n = 20) showed less pre-treatment activation during
response inhibition in a large cluster within the left DLPFC
(Figure 5). Additionally, they showed less activation in a smaller
region within the right DLPFC. Conversely, non-completers
displayed greater activation mainly in the medial PFC/frontal
pole and right inferior frontal gyrus prior to beginning DBT.
This pattern of higher activation was found in a larger spatial
extent within the medial PFC and right DLPFC in participants
who dropped out (n = 5) as compared to those who completed
approximately 7-months of treatment (p’s < 0.05). Participants
who did not initiate treatment, on the other hand, showed
less activation in two smaller areas of the PFC bilaterally and
showed higher activation to a similar spatial extent in the right
lateral PFC, as compared to those who initiated and remained in
treatment (p’s < 0.05). The main interactions for these analyses
are summarized in Table 8, while the simple effects analyses are
summarized in Tables 9–11.
Changes in activation for intention-to-treat analyses were
examined wherein pre-treatment observations were carried
forward for those who did not complete 7 months of treatment.
The pattern of activation across the PFC for intention-to-
treat analyses was similar to that observed in analyses using
completers alone, but with smaller clusters of significant change
(p’s< 0.5).
DISCUSSION
Consistent with randomized-controlled trials of DBT (Linehan
et al., 2006; McMain et al., 2009), participants with BPD
in the current study showed substantial declines in their
frequency of self-harm over the treatment period. Prior to
beginning treatment, patients had less activation in bilateral
middle/inferior frontal gyri during response inhibition. After
7 months of treatment, they showed significant gains in
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TABLE 6 | Multilevel analyses in all 16 channels examining the interaction
between Condition (no-go vs. cross-hair fixation), Time (pre-treatment vs.
7-month assessments) and Changes-In-Self-Harm.
fNIRS Channel b SE df t R2
β
1 0.0024 0.0007 58350.03 3.3780∗∗ 0.0002
2 0.0016 0.0008 61945.93 1.9160 0.0001
3 −0.0010 0.0007 62566.95 −1.4170 0.0000
4 0.0042 0.0009 60253.93 4.5750∗∗ 0.0003
5 0.0003 0.0007 62517.99 0.3980 0.0000
6 0.0025 0.0009 62442.98 2.8830∗ 0.0001
7 0.0004 0.0008 59383.06 0.4380 0.0000
8 0.0021 0.0010 54620.06 2.1260 0.0001
9 −0.0004 0.0008 57027.22 −0.4560 0.0000
10 0.0006 0.0010 58420.01 0.6640 0.0000
11 −0.0020 0.0011 59966.06 −1.9220 0.0001
12 0.0011 0.0008 61937.97 1.3010 0.0000
13 0.0004 0.0011 61444.97 0.3690 0.0000
14 0.0034 0.0009 62995.97 3.6410∗∗ 0.0002
15 0.0015 0.0008 60190.88 1.9440 0.0001
16 0.0019 0.0010 62758.65 1.9740 0.0001
Note: ∗∗p < 0.001, ∗p < 0.05. All models were estimated with an unstructured
covariance matrix and the Satterthwaite method of estimating degrees of freedom.
Significance levels were corrected using the False Discovery Rate approach.
activity in these same regions. Reductions in self-harm over
the treatment period were specifically related to right DLPFC
activation, even after statistically controlling for changes
in depression, mania, and BPD symptom severity, and
patients showing the greatest treatment gains showed lower
activation in this region prior to beginning DBT. Additionally,
treatment completers showed less activation in left DLPFC
before starting treatment, whereas non-completers displayed
higher activation in medial PFC and right inferior frontal
gyrus.
Reduced activation in bilateral middle/inferior frontal gyri
during response inhibition for patients with BPD prior to
beginning treatment likely reflects a diminished recruitment of
inhibitory control processes subserved by the PFC, especially
within the left DLPFC. This pattern of activity contrasts with
healthy adults on the same go/no-go task, who have shown
higher levels of activity in bilateral DLPFC during response
inhibition (compared to cross-hair fixation; Rodrigo et al.,
2014). These results also parallel studies that have used different
response inhibition tasks (e.g., emotional Stroop) in which
patients with BPD show differences in neural activation in left
inferior frontal gyrus under conditions of response inhibition
(Wingenfeld et al., 2009; Winter et al., 2015). Overall, these
findings indicate that before beginning treatment, patients with
BPD characterized by marked behavioral impulsivity (i.e., active
self-harm) show reduced activation in lateral areas of the
PFC responsible for motor inhibitory control (Aron et al.,
2004).
Despite showing significantly lower activity in bilateral
medial and inferior frontal gyri prior to beginning treatment,
patients exhibited increases in activity within these regions
after approximately 7 months of DBT. The right lateral PFC,
an area highly linked to impulse control (Aron et al., 2004),
showed a specific association with changes in frequency of self-
harm over the treatment period. Increases in activation within
this region were related to corresponding reductions in self-
harm after DBT. Remarkably, patients who went on to display
the greatest improvements in self-harm exhibited the lowest
activation in right DLPFC prior to beginning treatment; however,
they also demonstrated the greatest increases in activation in
this area after 7 months of DBT. These results suggest that self-
harming patients with BPD who show the lowest pre-treatment
engagement of prefrontal regions involved in motor control
TABLE 7 | Multilevel analyses examining the simple effects for channels with significant Condition (no-go vs. cross-hair fixation) × Time (pre-treatment
vs. 7-month assessments) × Changes-In-Self-Harm interactions.
fNIRS Channel b SE df t R2
β
Pre-Treatmet
Low Treatment Response Left DLPFC 1 −0.0802 0.0137 58350.20 −5.8390∗∗ 0.0006
4 −0.0578 0.0157 60253.96 −3.6890∗∗ 0.0002
6 −0.0415 0.0162 62442.97 −2.5630∗ 0.0001
Right DLPFC 14 −0.0575 0.0175 62995.97 −3.2900∗∗ 0.0002
High Treatment Response Left DLPFC 1 −0.1404 0.0209 58350.43 −6.7170∗∗ 0.0008
4 −0.1208 0.0231 60253.96 −5.2330∗∗ 0.0005
6 −0.0321 0.0249 62443.13 −1.2920 0.0000
Right DLPFC 14 −0.1560 0.0266 62996.05 −5.8600∗∗ 0.0005
After 7 months of DBT
Low Treatment Response Left DLPFC 1 −0.0800 0.0233 58349.95 −0.3430 0.0000
4 −0.0617 0.0300 60253.93 −2.0560∗ 0.0001
6 −0.1067 0.0284 62442.95 −3.7570∗∗ 0.0002
Right DLPFC 14 −0.0580 0.0310 62995.98 −1.8710 0.0001
High Treatment Response Left DLPFC 1 0.1092 0.0329 58349.95 3.3230∗∗ 0.0002
4 0.1905 0.0433 60253.93 4.4040∗∗ 0.0003
6 0.0882 0.0401 62442.95 2.1990∗ 0.0001
Right DLPFC 14 0.0977 0.0436 62995.96 2.2410∗ 0.0001
Note: ∗∗p < 0.01, ∗p < 0.05. All models were estimated with an unstructured covariance matrix and the Satterthwaite method of estimating degrees of freedom.
Significance levels are FDR corrected.
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FIGURE 5 | Pre-treatment differences in activation during response inhibition for patients who completed treatment and did not complete treatment.
(as well as other aspects of self-regulation) may have the most
to gain from a psychological treatment intended to increase
behavioral and emotional control. Moreover, these potential
neural markers of treatment response appear to be detectable
even before patients begin treatment.
Patients who ultimately did not complete treatment displayed
more activation in the medial PFC and right inferior frontal
gyrus before starting DBT. Conversely, treatment completers
showed less activation in a large region of the left DLPFC prior to
beginning DBT. Heightened activity in the right inferior frontal
gyrus, a region critical for impulse control, appears to represent
a risk factor that may prospectively predict which patients will
not complete treatment. It is possible that control processes
subserved by the PFC are more efficiently recruited in this
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TABLE 8 | Multilevel analyses in all 16 channels examining the interaction
between Condition (no-go vs. cross-hair fixation) and Treatment
Completion Status (completers vs. non-completers).
fNIRS b SE df t R2
β
Channel
1 −0.0480 0.0145 35139.24 −3.3030∗∗ 0.0003
2 −0.0123 0.0155 37900.06 −0.7960 0.0000
3 −0.0540 0.0142 38344.06 −3.8020∗∗ 0.0004
4 −0.0414 0.0162 37444.04 −2.5600∗ 0.0002
5 −0.1156 0.0134 38391.11 −8.6120∗∗ 0.0019
6 −0.0704 0.0159 37933.02 −4.4130∗∗ 0.0005
7 −0.1047 0.0141 36263.39 −7.4220∗∗ 0.0015
8 −0.0298 0.0174 32282.18 −1.7110 0.0001
9 −0.0876 0.0160 34072.27 −5.4620∗∗ 0.0009
10 −0.0634 0.0163 36605.21 −3.8980∗∗ 0.0004
11 −0.0634 0.0127 38260.13 −4.9810∗∗ 0.0006
12 0.0213 0.0147 37865.12 1.4460 0.0001
13 −0.0581 0.0131 39047.12 −4.4220∗∗ 0.0005
14 −0.0337 0.0169 39145.02 −1.9940 0.0001
15 −0.0050 0.0151 36179.00 −0.3300 0.0000
16 −0.0622 0.0176 38272.81 −3.5380∗∗ 0.0003
Note: ∗∗p < 0.001, ∗p < 0.05. All models were estimated with an unstructured
covariance matrix and the Satterthwaite method of estimating degrees of freedom.
Significance levels were corrected using the False Discovery Rate approach.
TABLE 9 | Multilevel analyses examining the simple effects for significant
interaction between Condition (no-go vs. cross-hair fixation) and
Treatment Completion Status (completers vs. non-completers).
fNIRS Channel b SE df t R2
β
Completers
(n = 19)
1 −0.1243 0.0158 35139.2230 −7.8820∗∗ 0.0018
3 −0.0788 0.0149 38344.0410 −5.2760∗∗ 0.0007
4 −0.0966 0.0168 37443.9980 −5.7470∗∗ 0.0009
5 −0.0632 0.0152 38391.0470 −4.1510∗∗ 0.0004
6 −0.0822 0.0175 37933.0210 −4.7050∗∗ 0.0006
7 −0.0390 0.0153 36262.2080 −2.5430∗ 0.0002
9 −0.0148 0.0176 34072.3360 −0.8450 0.0000
10 −0.0268 0.0174 36605.0160 −1.5360 0.0001
11 −0.0316 0.0142 38260.2510 −2.2200∗ 0.0001
13 −0.0517 0.0144 39047.0440 −3.5870∗ 0.0003
16 −0.0324 0.0183 38271.6950 −1.7690 0.0001
Non-Completers
(n = 10)
1 −0.0283 0.0244 35139.2390 −1.1620 0.0000
3 0.0291 0.0241 38344.0710 1.2060 0.0000
4 −0.0139 0.0276 37444.0590 −0.5030 0.0000
5 0.1680 0.0221 38391.1350 7.5970∗∗ 0.0015
6 0.0585 0.0267 37933.0140 2.1940∗ 0.0001
7 0.1705 0.0237 36263.8770 7.1950∗∗ 0.0014
9 0.1604 0.0269 34072.2410 5.9750∗∗ 0.0010
10 0.1001 0.0275 36605.2920 3.6420∗∗ 0.0004
11 0.0951 0.0211 38260.0710 4.5110∗∗ 0.0005
13 0.0645 0.0220 39047.1570 2.9360∗∗ 0.0002
16 0.0921 0.0300 38273.2120 3.0660∗∗ 0.0002
Note: ∗∗p < 0.001, ∗p < 0.05. All models were estimated with an unstructured
covariance matrix and the Satterthwaite method of estimating degrees of freedom.
Significance levels are FDR corrected.
subset of patients as compared to treatment completers, who
showed less activation in a roughly homologous region in the
left hemisphere. Higher levels of activation in the medial PFC, a
TABLE 10 | Multilevel analyses exploring simple effects of the significant
Inhibitory Control × Treatment Completion interaction for those who
dropped out of treatment.
fNIRS b SE df t R2
β
Channel
At Pre-Treatment
1 −0.0976 0.0124 58357.19 −7.8800∗∗ 0.0008
2 −0.0525 0.0137 61952.97 −3.8230∗∗ 0.0005
3 −0.0500 0.0119 62573.99 −4.2020∗∗ 0.0001
4 −0.0758 0.0139 60260.97 −5.4620∗∗ 0.0004
12 −0.0306 0.0139 61945.06 −2.1930∗ 0.0002
14 −0.0864 0.0156 63002.98 −5.5350∗∗ 0.0002
15 −0.0215 0.0136 60197.92 −1.5850 0.0002
16 0.0005 0.0162 62766.45 0.0320 0.0006
After 7 months
of DBT
1 0.0366 0.0148 58356.94 2.4660∗ 0.0001
2 0.0705 0.0168 61952.93 4.1940∗∗ 0.0003
3 0.0064 0.0146 62573.94 0.4400 0.0000
4 0.0344 0.0177 60260.92 1.9450 0.0001
12 0.0495 0.0171 61944.96 2.8940∗∗ 0.0001
14 0.0020 0.0195 63002.99 0.1040 0.0000
15 0.0492 0.0163 60197.85 3.0220∗∗ 0.0002
16 0.1617 0.0199 62765.59 8.1040∗∗ 0.0010
Note: ∗∗p < 0.001, ∗p < 0.05. All models were estimated with an unstructured
covariance matrix and the Satterthwaite method of estimating degrees of freedom.
Significance levels are FDR corrected.
TABLE 11 | Multilevel analyses exploring simple effects of the significant
Inhibitory Control × Treatment Completion interaction for those who
never initiated treatment.
fNIRS Channel b SE df t R2
β
6 −0.0338 0.0122 53960.95 −2.771∗ 0.0001
8 0.0140 0.0135 46651.03 1.0420 0.0000
10 0.0029 0.0123 49939.09 0.2330 0.0000
12 0.0187 0.0119 53387.97 1.5780 0.0000
14 −0.0489 0.0132 54493.98 −3.7170∗∗ 0.0003
15 0.0135 0.0111 51818.83 1.2150 0.0000
16 0.0656 0.0130 54461.77 5.0310∗∗ 0.0005
Note: ∗∗p < 0.001, ∗p < 0.05. All models were estimated with an unstructured
covariance matrix and the Satterthwaite method of estimating degrees of freedom.
Significance levels are FDR corrected.
neural region involved in self-referential thinking (Gusnard et al.,
2001), could also reflect an increased focus on the self in relation
to others among patients at risk for treatment non-completion.
Indeed, increased activation in medial PFC is observed in
patients with BPD engaged in social-cognitive activities (Ruocco
et al., 2010; Domsalla et al., 2014), possibly reflecting so-called
‘‘hyper-mentalizing’’ (i.e., heightened attention to one’s own
intentional mental states and that of others), which is considered
central to developmental theories of the disorder (Fonagy and
Bateman, 2008). This is a speculative interpretation of these
results; however, they may be relevant to social and interpersonal
dynamics that could impact the degree of engagement in
psychotherapy.
A main limitation of this study is its focus on the PFC,
which although strongly linked to response inhibition (Rodrigo
et al., 2014), is one hub of a larger brain network subserving
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this cognitive ability (Swick et al., 2011). Whereas the fNIRS
system employed in this study primarily accesses the anterior
portion of the frontal cortex, an important advantage of the
technique is that it affords high temporal resolution and is both
portable and cost-effective, which may facilitate its translation
to clinical settings (Irani et al., 2007). For these results to have
an applied clinical value, however, replication in a larger cohort
of patients using a randomized-controlled design in a formal
clinical trial is necessary. Indeed, prospective investigation of
the predictive utility of these biomarkers will assist in validating
the current findings, especially in relation to their incremental
validity over other clinical measures. Furthermore, examination
of the test-retest reliability of fNIRS requires further study to
establish the potential clinical utility of these findings. While
the present study was naturalistic in its design and included
patients with BPD who were treated as part of regular clinical
services and were mostly on medications and had high levels of
psychiatric diagnostic comorbidity, these results may be more
generalizable to the typical DBT treatment setting with self-
harming patients with BPD. Additionally, factors such as age,
gender, and handedness could potentially impact the results of
this work. Future research with adequately large sample sizes
should address these questions while also extending the present
findings to interactions between response inhibition and affective
processes. It is also important to note that, given the preliminary
nature of the present study, it is premature to draw specific
conclusions about the effectiveness of fNIRS for predicting
treatment outcomes at the level of an individual patient. These
results provide initial evidence for potential neuroimaging-based
biomarkers that may be used to prospectively predict treatment
outcomes. Importantly, these findings must be replicated in
independent samples using appropriate statistical techniques
to assess the sensitivity and specificity of the biomarkers for
predicting treatment outcomes.
In summary, the potential implication of this research is
that distinct patterns of neural activity in areas of the PFC
reflecting treatment responses to DBT and attrition from
therapy may be detectable even before patients start treatment.
Research to validate these potential biomarkers reflecting future
treatment outcomes may assist in identifying at-risk patients and
intervening earlier in the course of self-harm to prevent potential
serious injury and suicide. Ultimately, this work may also help
to reduce self-harm in more vulnerable patients identified using
these candidate biomarkers by increasing the intensity of DBT or
diverting these patients toward alternative interventions.
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